- Previous Close
165.02 - Open
164.00 - Bid --
- Ask --
- Day's Range
162.83 - 165.40 - 52 Week Range
144.80 - 200.33 - Volume
1,478,575 - Avg. Volume
3,012,700 - Market Cap (intraday)
73.039B - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
29.87 - EPS (TTM)
5.46 - Earnings Date May 6, 2025
- Forward Dividend & Yield 2.00 (1.23%)
- Ex-Dividend Date Apr 21, 2025
- 1y Target Est
199.99
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
www.zoetis.com13,800
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ZTS
View MorePerformance Overview: ZTS
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZTS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZTS
View MoreValuation Measures
Market Cap
73.04B
Enterprise Value
77.80B
Trailing P/E
29.82
Forward P/E
27.10
PEG Ratio (5yr expected)
2.88
Price/Sales (ttm)
8.02
Price/Book (mrq)
15.31
Enterprise Value/Revenue
8.41
Enterprise Value/EBITDA
20.18
Financial Highlights
Profitability and Income Statement
Profit Margin
26.86%
Return on Assets (ttm)
14.87%
Return on Equity (ttm)
51.14%
Revenue (ttm)
9.26B
Net Income Avi to Common (ttm)
2.49B
Diluted EPS (ttm)
5.46
Balance Sheet and Cash Flow
Total Cash (mrq)
1.99B
Total Debt/Equity (mrq)
143.17%
Levered Free Cash Flow (ttm)
2.37B